News
Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update
DSR (Direct Sodium Removal) heart failure drug development:
…
Destiny Pharma announces positive update from US FDA on XF-73 Phase 3 development plans
FDA clarifies Phase 3 and US registration pathway for XF-73…
ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer
Recognition of commendable, longstanding dedication to the…
Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion’s MAFTEST® reduces the risk of death in comparison with current clinical guidance
MAFTEST® analyses of the NSABP-B34 and AZURE landmark clinical…
Invizius Announces Appointment of Peter Stenvinkel, Professor of Nephrology at Karolinska Institutet, to the Clinical Advisory Board
World leading expert and key opinion leader in nephrology
Glasgow,…
Declaration of conformity drawn up for Inbiomotion MAFTEST®
Barcelona, July 13 2022, On 13 May 2022, the conformity assessment…
Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi
Neuraxpharm, the central nervous system (CNS) specialist, to…
vasopharm GmbH Announces Brain Lactate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury
Ronopterin significantly reduces lactate levels in brain microdialysate…
Ariceum Therapeutics Appoints Chief Business Officer
BERLIN, 7 July 2022 – Ariceum Therapeutics (Ariceum), a private…
DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura®
Parsippany, N.J. and Turku, Finland – July 6, 2022 – IVERIC…
Destiny Pharma announces start of a new XF-73 research programme
Destiny Pharma announces start of a new XF-73 research programme
Aim…
Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data
Kyowa Kirin expands the license agreement with one new ADC…
eTheRNA: New agreement paves way for development of first African-owned COVID-19 vaccine
A year after the establishment of the mRNA Vaccine Technology…
Versameb to Present during World Continence Week 2022
Lead therapeutic candidate has the potential to treat Stress…
Nordic Bioscience and Roche Diagnostics Strengthen Collaboration for Development of Biomarkers for Chronic Diseases
Nordic Bioscience, a growing biomarker company, today announced…
Biocomposites appoints Group Chief Financial Officer and New UK General Manager
Keele, UK, 15 June 2022 – Biocomposites, an international…
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Top-line data expected from ENHANCE-2 in Q3 2022 and ENHANCE-1…
Synklino completes Series A raise of EUR 29.8 million to advance clinical trials of its drug candidate for the treatment of Cytomegalovirus (CMV)
PKA pension fund lead investment, alongside The Danish Growth…
ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb’s iPREDICT Phase IIb Study
Los Angeles, California, USA, June 8th, 2022 – ImaginAb Inc.,…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
